Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5183886 | 1.00 | SRD5A1 (0.53) | SRD5A1CYP19A1CYP17A1SRD5A2 | |
| SCHEMBL6673554 | 0.84 | SRD5A1 (0.42) | SRD5A1SRD5A2 | |
| SCHEMBL3797856 | 0.84 | CYP19A1 (0.58) | SRD5A1CYP19A1 | |
| SCHEMBL7529519 | 0.84 | CYP19A1 (0.58) | SRD5A1CYP19A1 | |
| SCHEMBL8707348 | 0.83 | SRD5A1 (0.51) | SRD5A1CYP19A1 | |
| SCHEMBL3802034 | 0.81 | SRD5A1 (0.53) | SRD5A1CYP19A1CYP17A1SRD5A2 | |
| SCHEMBL6673559 | 0.80 | KDM4E (0.44) | SRD5A1SRD5A2 | |
| SCHEMBL8707338 | 0.80 | CYP19A1 (0.46) | CYP19A1 | |
| SCHEMBL6678791 | 0.80 | CYP19A1 (0.40) | CYP19A1 | |
| SCHEMBL6678788 | 0.80 | CYP19A1 (0.40) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335930-B1 | Process for the preparation of 3-oxo-4-azasteroids | GLAXO GROUP LTD (GB) | 2004-10-13 | — | — | EP | claimed |
| US-6794508-B2 | Process | SMITHKLINE BEECHAM CORPORATION | 2004-09-21 | — | — | US | claimed |
| US-20040049042-A1 | Process | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | claimed |
| EP-1335930-A2 | PROCESS | GLAXO GROUP LIMITED (GB) | 2003-08-20 | — | — | EP | claimed |
| WO-2002046207-A2 | PROCESS | GLAXO GROUP LIMITED (GB) | 2002-06-13 | — | — | WO | claimed |
| EP-1539703-A4 | METHOD FOR THE SELECTIVE PREPARATION OF 3-OXO-4-AZA-5A-ANDROSTANE COMPOUND | HANMI PHARM IND CO LTD (KR) | 2007-02-21 | — | — | EP | disclosed |
| EP-1539703-A4 | METHOD FOR THE SELECTIVE PREPARATION OF 3-OXO-4-AZA-5A-ANDROSTANE COMPOUND | HANMI PHARM IND CO LTD (KR) | 2007-02-21 | — | — | EP | disclosed |
| US-7084274-B2 | Method for the selective preparation of 3-oxo-4-aza-5α-androstane compound | HANMI PHARM. CO., LTD. (KR) | 2006-08-01 | — | — | US | disclosed |
| US-7084274-B2 | Method for the selective preparation of 3-oxo-4-aza-5α-androstane compound | HANMI PHARM. CO., LTD. (KR) | 2006-08-01 | — | — | US | disclosed |
| US-20060019979-A1 | Method for the selective preparation of 3-oxo-4-aza-5a androstane compound | HANMI PHARM. CO., LTD (KR) | 2006-01-26 | — | — | US | disclosed |
| US-20060019979-A1 | Method for the selective preparation of 3-oxo-4-aza-5a androstane compound | HANMI PHARM. CO., LTD (KR) | 2006-01-26 | — | — | US | disclosed |
| EP-1539703-A1 | METHOD FOR THE SELECTIVE PREPARATION OF 3-OXO-4-AZA-5A-ANDROSTANE COMPOUND | Hanmi Pharm. Co., Ltd. (KR) | 2005-06-15 | — | — | EP | disclosed |
| WO-1993023420-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5237064-A | Process for producing 7β-substituted-aza-5αandrostan-3-ones | MERCK & CO., INC. (US) | 1993-08-17 | — | — | US | disclosed |
| WO-1993014762-A1 | 17β-HYDROXYBENZOYL-4-AZA-5α-ANDROST-1-EN-3-ONES USEFUL TO TREAT BALDNESS | MERCK & CO., INC. (US) | 1993-08-05 | — | — | WO | disclosed |
| EP-0004949-B1 | 4-AZA-17-SUBSTITUTED-5-ALPHA-ANDROSTAN-3-ONE, THEIR A AND D HOMO ANALOGS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1983-09-21 | — | — | EP | disclosed |
| US-4377584-A | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors | MERCK & CO., INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4220775-A | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors | MERCK & CO., INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4220775-A | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors | MERCK & CO., INC. (US) | 1980-09-02 | — | — | US | disclosed |
| EP-0004949-A1 | 4-Aza-17-substituted-5-alpha-androstan-3-one, their A and D homo analogs, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019979-A1 | Method for the selective preparation of 3-oxo-4-aza-5a androstane compound | HSD3B2, CYP19A1, CYP17A1 | SRD5A1 11/4885CYP19A1 2/4885CYP17A1 3/4885 |
| US-20040049042-A1 | Process | SRD5A2, SRD5A1, HSD3B1 | SRD5A1 2/4885CYP19A1 18/4885CYP17A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.